Navigation Links
CryoLife Receives Expanded Indication for BioFoam in Europe
Date:12/5/2012

ATLANTA, Dec. 5, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it has received regulatory approval in Europe to market its BioFoam® Surgical Matrix as an adjunct to hemostasis in cardiovascular surgery when cessation of bleeding by ligature or other conventional methods is ineffective or impractical.  BioFoam has previously been approved in Europe as an adjunct to hemostasis in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical.

"We are pleased to receive an expanded indication for BioFoam in Europe," said Steven G. Anderson, CryoLife president and chief executive officer. "We have been encouraged by the early clinical experience in Europe with liver and spleen procedures and believe the product is well suited to provide rapid hemostasis in cardiovascular surgeries.  This expanded indication aligns with our BioGlue and PerClot market opportunity in Europe, giving us another sales driver and product to add to our selling efforts for our core cardiovascular surgeon customers.  BioFoam is an important extension to our portfolio, providing a solution for cardiac surgical needs, as a combination sealant/hemostat."

CryoLife estimates the annual European market opportunity for BioFoam, including for cardiovascular and parenchymal tissues, BioGlue and PerClot is more than $100 million[1].

[1] Based on Millennium Research Group (European Markets for Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers 2012; and European Surgical Procedure Volumes 2010) and Company estimates.

About BioFoam

BioFoam, a protein hydrogel biomaterial developed by CryoLife, contains an expansi
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
2. CryoLife Completes Acquisition of Hemosphere
3. CryoLife to Participate in 3rd Annual Benchmark Company, LLC One-on-One Investor Conference
4. CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
5. CryoLife Reports 13% Revenue Growth for Second Quarter 2012
6. CryoLife Announces Initiation of Quarterly Cash Dividend
7. CryoLife Reports 13% Revenue Growth for Third Quarter 2012
8. CryoLife to Participate in Lazard Capital Markets 9th Annual Healthcare Conference
9. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
10. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
11. Nephros Receives 510(k) Clearance for Hemodiafiltration System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... -- NxStage Medical, Inc. (Nasdaq: NXTM ), a leading ... H. Burbank , Chief Executive Officer, will present at the ... on Wednesday, March 11 th at 3:50 ... be made available at http://ir.nxstage.com  at the time ... NxStage Medical, Inc. (Nasdaq: NXTM ) is a ...
(Date:3/4/2015)... 4, 2015 XBiotech announced today that ... patients with moderate to severe plaque psoriasis have ... II trial evaluated the potential benefit of MABp1, ... interleukin-1 alpha (IL-1a). IL-1a is a pro-inflammatory cytokine ... skin lesions. The Company claims that blockade of ...
(Date:3/4/2015)... Pa. , March 4, 2015  Results of ... 100 Consecutive Cases Using MarginProbe for Intra-Operative Positive Margin ... poster session at the 32 nd Annual Miami ... study, conducted by Moshe Papa , MD, FACS, ... at Tel Aviv University, reports an analysis of MarginProbe,s ...
Breaking Medicine Technology:NxStage to Present at the Barclays Capital Global Healthcare Conference 2XBiotech Announces Phase II Psoriasis Study Results in JAMA Dermatology 2New Study Shows Breast Re-excision Rates Significantly Reduced in 100 Consecutive Cases 2
... Calif., Sept. 1, 2011 Isis Pharmaceuticals, Inc. (Nasdaq: ... that management will present a company overview at Stifel Nicolaus, ... p.m. ET at the Four Seasons Hotel in Boston. ... available on the "Investors & Media" section of the Company,s ...
... Sept. 1, 2011 People seeking support ... prepare to be disappointed – and to make a ... cardiologist, Dr. Carl Lavie, medical director of Cardiac Rehabilitation ... Orleans, LA, "flush-free" niacin may not cause flushing, but ...
Cached Medicine Technology:Leading Expert's Heart Health Advice: Flush Your "Flush-Free" Dietary Supplement Niacin 2Leading Expert's Heart Health Advice: Flush Your "Flush-Free" Dietary Supplement Niacin 3
(Date:3/4/2015)... When people talk about venues being the place ... numerous genres, the Houston Rodeo will be a ... the annual livestock show and rodeo, one popular band will ... being held at the event. The 2015 show will feature ... try and get the festival its largest attendance ever. , ...
(Date:3/4/2015)... York, New York (PRWEB) March 04, 2015 ... http://www.lipitorlawsuitcenter.com/ ) that allege the statin drug caused patients ... in the U.S. District Court, District of South Carolina. ... will be convened on March 26, 2015 at 10:00 ... been directed to submit a Joint Status report to ...
(Date:3/4/2015)... Church, VA (PRWEB) March 04, 2015 ... Four Hours , **FDAnews Webinar**, March 24, 2015 — ... , FDA investigators generally know within four hours of ... If the manufacturer is on their “good” list, they’ll ... doing. If a manufacturer is on the “bad” list, ...
(Date:3/4/2015)... 2015 The ability of volumetric ... assessment and help improve breast cancer risk prediction ... for presentation at the European Congress of Radiology ... - eight posters and 2 session presentations - ... density and quantitative breast imaging software tools to ...
(Date:3/4/2015)... growing influence of movies, television, video games and the internet ... with the increasingly frantic lifestyle of modern parents, it can ... what kids are into these days. It seems that every ... , The same is also true for drugs and alcohol. ... talk about them, are constantly changing. These tips put a ...
Breaking Medicine News(10 mins):Health News:Cheap Houston Rodeo Tickets: Ticket Down Slashes Houston Rodeo Tickets for John Legend, Pitbull, Alan Jackson, Tim McGraw, Zac Brown Band, Fall Out Boy & Miranda Lambert 2Health News:Cheap Houston Rodeo Tickets: Ticket Down Slashes Houston Rodeo Tickets for John Legend, Pitbull, Alan Jackson, Tim McGraw, Zac Brown Band, Fall Out Boy & Miranda Lambert 3Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2
... Risky Business: Managing the Quality of ... Edition by FDAnews. Authored by Robert A. Rhoades, ... Associates Consulting (Washington, DC), the book offers insights from ... update for the Second Edition is timely in light ...
... Employers spend more than $13 billion annually in medical costs ... number one health threat by the CDC. Obese workers are ... injury and accidents and incur higher medical costs than employees ... employers address this issue. Health Advocate(TM), the nation,s ...
... HMS Holdings Corp. (Nasdaq: HMSY ) today announced ... Services Conference, which will be held February 9-11, ... will present on Monday, February 9th at 12:30 pm Eastern ... is the nation,s leader in coordination of benefits and ...
... of fibroblasts during development also promotes their ability to ... in the February 9, 2009 issue of the ... epithelial cells into fibroblast-like mesenchymal cells is a critical ... factor Snail1 induces this conversion (known as epithelialmesenchymal transition, ...
... Leading Factor in Improving Formulary Placement of ... a New Report from HealthLeaders-InterStudy ... N.J., Feb. 2 HealthLeaders-InterStudy and Fingertip ... surveyed pharmacy directors expect to reimburse both ...
... 2 Calling all high school seniors --,there are ... 2009 Scholar Athlete Milk,Mustache of the Year (SAMMY) Awards ... This unique award, sponsored by ... USA TODAY, educates teens on the importance of,making smart ...
Cached Medicine News:Health News:New Book Prescribes Quality Guidance for Pharma Industry as Criticism of FDA and Consumer Safety Concerns Surge 2Health News:Health Advocate Releases Obesity White Paper: Strategies and Programs to Reduce Obesity in the Workplace 2Health News:Health Advocate Releases Obesity White Paper: Strategies and Programs to Reduce Obesity in the Workplace 3Health News:Fibroblasts invade at a snail's pace 2Health News:Less Than Two-Thirds of Surveyed Pharmacy Directors Expect to Reimburse Both Onglyza and Alogliptin Once They are Available for the Treatment of Type 2 Diabetes 2Health News:Less Than Two-Thirds of Surveyed Pharmacy Directors Expect to Reimburse Both Onglyza and Alogliptin Once They are Available for the Treatment of Type 2 Diabetes 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: